117 related articles for article (PubMed ID: 22137341)
1. Identification of oxazolidinediones and thiazolidinediones as potent 17β-hydroxysteroid dehydrogenase type 3 inhibitors.
Harada K; Kubo H; Tanaka A; Nishioka K
Bioorg Med Chem Lett; 2012 Jan; 22(1):504-7. PubMed ID: 22137341
[TBL] [Abstract][Full Text] [Related]
2. Development of hormone-dependent prostate cancer models for the evaluation of inhibitors of 17beta-hydroxysteroid dehydrogenase type 3.
Day JM; Tutill HJ; Foster PA; Bailey HV; Heaton WB; Sharland CM; Vicker N; Potter BV; Purohit A; Reed MJ
Mol Cell Endocrinol; 2009 Mar; 301(1-2):251-8. PubMed ID: 18786604
[TBL] [Abstract][Full Text] [Related]
3. Coumarins as novel 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for potential treatment of prostate cancer.
Harada K; Kubo H; Tomigahara Y; Nishioka K; Takahashi J; Momose M; Inoue S; Kojima A
Bioorg Med Chem Lett; 2010 Jan; 20(1):272-5. PubMed ID: 19954971
[TBL] [Abstract][Full Text] [Related]
4. Discovery of potent and orally bioavailable 17β-hydroxysteroid dehydrogenase type 3 inhibitors.
Harada K; Kubo H; Abe J; Haneta M; Conception A; Inoue S; Okada S; Nishioka K
Bioorg Med Chem; 2012 May; 20(10):3242-54. PubMed ID: 22512907
[TBL] [Abstract][Full Text] [Related]
5. Identification of novel functional inhibitors of 17beta-hydroxysteroid dehydrogenase type III (17beta-HSD3).
Spires TE; Fink BE; Kick EK; You D; Rizzo CA; Takenaka I; Lawrence RM; Ruan Z; Salvati ME; Vite GD; Weinmann R; Attar RM; Gottardis MM; Lorenzi MV
Prostate; 2005 Oct; 65(2):159-70. PubMed ID: 15924334
[TBL] [Abstract][Full Text] [Related]
6. The design of novel 17beta-hydroxysteroid dehydrogenase type 3 inhibitors.
Vicker N; Sharland CM; Heaton WB; Gonzalez AM; Bailey HV; Smith A; Springall JS; Day JM; Tutill HJ; Reed MJ; Purohit A; Potter BV
Mol Cell Endocrinol; 2009 Mar; 301(1-2):259-65. PubMed ID: 18775469
[TBL] [Abstract][Full Text] [Related]
7. Development of 3-substituted-androsterone derivatives as potent inhibitors of 17β-hydroxysteroid dehydrogenase type 3.
Maltais R; Fournier MA; Poirier D
Bioorg Med Chem; 2011 Aug; 19(15):4652-68. PubMed ID: 21741247
[TBL] [Abstract][Full Text] [Related]
8. Identification of a novel series of tetrahydrodibenzazocines as inhibitors of 17beta-hydroxysteroid dehydrogenase type 3.
Fink BE; Gavai AV; Tokarski JS; Goyal B; Misra R; Xiao HY; Kimball SD; Han WC; Norris D; Spires TE; You D; Gottardis MM; Lorenzi MV; Vite GD
Bioorg Med Chem Lett; 2006 Mar; 16(6):1532-6. PubMed ID: 16386902
[TBL] [Abstract][Full Text] [Related]
9. Structure-based design, synthesis and in vitro characterization of potent 17beta-hydroxysteroid dehydrogenase type 1 inhibitors based on 2-substitutions of estrone and D-homo-estrone.
Möller G; Deluca D; Gege C; Rosinus A; Kowalik D; Peters O; Droescher P; Elger W; Adamski J; Hillisch A
Bioorg Med Chem Lett; 2009 Dec; 19(23):6740-4. PubMed ID: 19836949
[TBL] [Abstract][Full Text] [Related]
10. Design, chemical synthesis and biological evaluation of 3-spiromorpholinone/3-spirocarbamate androsterone derivatives as inhibitors of 17β-hydroxysteroid dehydrogenase type 3.
Djigoué GB; Kenmogne LC; Roy J; Maltais R; Poirier D
Bioorg Med Chem; 2015 Sep; 23(17):5433-51. PubMed ID: 26277760
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, biochemical evaluation and rationalisation of the inhibitory activity of a series of 4-hydroxyphenyl ketones as potential inhibitors of 17beta-hydroxysteroid dehydrogenase type 3 (17beta-HSD3).
Lota RK; Dhanani S; Owen CP; Ahmed S
Bioorg Med Chem Lett; 2006 Sep; 16(17):4519-22. PubMed ID: 16797984
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, biochemical evaluation and rationalisation of the inhibitory activity of a range of 4-hydroxyphenyl ketones as potent and specific inhibitors of the type 3 of 17beta-hydroxysteroid dehydrogenase (17beta-HSD3).
Lota RK; Olusanjo MS; Dhanani S; Owen CP; Ahmed S
J Steroid Biochem Mol Biol; 2008 Jul; 111(1-2):128-37. PubMed ID: 18620056
[TBL] [Abstract][Full Text] [Related]
13. Oxazolones as potent inhibitors of 11beta-hydroxysteroid dehydrogenase type 1.
Sutin L; Andersson S; Bergquist L; Castro VM; Danielsson E; James S; Henriksson M; Johansson L; Kaiser C; Flyrén K; Williams M
Bioorg Med Chem Lett; 2007 Sep; 17(17):4837-40. PubMed ID: 17600707
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of human and rat 3beta-hydroxysteroid dehydrogenase and 17beta-hydroxysteroid dehydrogenase 3 activities by perfluoroalkylated substances.
Zhao B; Hu GX; Chu Y; Jin X; Gong S; Akingbemi BT; Zhang Z; Zirkin BR; Ge RS
Chem Biol Interact; 2010 Oct; 188(1):38-43. PubMed ID: 20619251
[TBL] [Abstract][Full Text] [Related]
15. Steroidal lactones as inhibitors of 17beta-hydroxysteroid dehydrogenase type 5: chemical synthesis, enzyme inhibitory activity, and assessment of estrogenic and androgenic activities.
Bydal P; Luu-The V; Labrie F; Poirier D
Eur J Med Chem; 2009 Feb; 44(2):632-44. PubMed ID: 18472187
[TBL] [Abstract][Full Text] [Related]
16. 3Beta-alkyl-androsterones as inhibitors of type 3 17beta-hydroxysteroid dehydrogenase: inhibitory potency in intact cells, selectivity towards isoforms 1, 2, 5 and 7, binding affinity for steroid receptors, and proliferative/antiproliferative activities on AR+ and ER+ cell lines.
Ngatcha BT; Laplante Y; Labrie F; Luu-The V; Poirier D
Mol Cell Endocrinol; 2006 Mar; 248(1-2):225-32. PubMed ID: 16359782
[TBL] [Abstract][Full Text] [Related]
17. Effects of methoxychlor and 2,2-bis(p-hydroxyphenyl)-1,1,1-trichloroethane on 3β-hydroxysteroid dehydrogenase and 17β-hydroxysteroid dehydrogenase-3 activities in human and rat testes.
Hu GX; Zhao B; Chu Y; Li XH; Akingbemi BT; Zheng ZQ; Ge RS
Int J Androl; 2011 Apr; 34(2):138-44. PubMed ID: 20522127
[TBL] [Abstract][Full Text] [Related]
18. Design and validation of specific inhibitors of 17beta-hydroxysteroid dehydrogenases for therapeutic application in breast and prostate cancer, and in endometriosis.
Day JM; Tutill HJ; Purohit A; Reed MJ
Endocr Relat Cancer; 2008 Sep; 15(3):665-92. PubMed ID: 18541621
[TBL] [Abstract][Full Text] [Related]
19. Discovery of nonsteroidal 17beta-hydroxysteroid dehydrogenase 1 inhibitors by pharmacophore-based screening of virtual compound libraries.
Schuster D; Nashev LG; Kirchmair J; Laggner C; Wolber G; Langer T; Odermatt A
J Med Chem; 2008 Jul; 51(14):4188-99. PubMed ID: 18533708
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and biological evaluation of bis(hydroxyphenyl) azoles as potent and selective non-steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases.
Bey E; Marchais-Oberwinkler S; Kruchten P; Frotscher M; Werth R; Oster A; Algül O; Neugebauer A; Hartmann RW
Bioorg Med Chem; 2008 Jun; 16(12):6423-35. PubMed ID: 18514529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]